+44-7360-538437- Biomedical Research (2014) Volume 25, Issue 4
Percutaneous biliary metallic stenting and 125I seed implantation for the treatment of malignant obstructive jaundice.
This study aimed to investigate the feasibility and efficacy of percutaneous biliary metallic stenting and 125I seed implantation in treatment of malignant obstructive jaundice (MOJ). Percutaneous biliary metallic stenting and 125I seed implantation were performed in 27 patients with MOJ. Detection of liver function, routine blood test and upper abdominal CT were done to evaluate the change in bilirubin, blood components, stability of seed and stent patency. Percutaneous metallic stenting and 125I seed implantation were smoothly performed in the biliary tract with the success rate of 100%. The mean number of 125I seeds used was 17 per patient. The median period of follow up was 7 months (range: 3-19 months). Imaging examination showed the seeds were stable and had no displacement. The total bilirubin reduced from 369.45±87.32μmol/L before surgery to 96.03±70.14μmol/L at 1 month after surgery. Side effects of radiotherapy (such as leukopenia, nausea and vomiting) were not observed. Re-stenosis was found in 2 patients with the re-stenosis rate of 7.4%. Two patients died of systemic failure within 3 months after surgery, and the mean survival time of these patients was 201.8± 178.7 days. Percutaneous biliary metallic stenting and 125I seed implantation are safe and feasible for patients with MOJ and may serve as a minimally invasive strategy for the prevention of restenosis after biliary stent implantation.
Author(s): Song Wang, Chunpeng Yu, Jiafeng zhu